Question 19

The iPLEDGE program is mandated for isotretinoin due to its severe teratogenic risks.

The iPLEDGE program is specifically designed for isotretinoin, a medication that carries a high risk of causing severe birth defects if taken during pregnancy. This program ensures that all patients, prescribers, and pharmacists adhere to strict guidelines to prevent fetal exposure.

A) dofetilide.

Dofetilide is an antiarrhythmic medication used to treat certain types of irregular heartbeat. While it has its own risks and side effects, it is not associated with severe teratogenic effects that would necessitate a program like iPLEDGE.

B) clozapine.

Clozapine is an antipsychotic medication used for treatment-resistant schizophrenia. Although it requires monitoring for agranulocytosis and has other risks, it does not pose significant teratogenic risks that would require the stringent controls of the iPLEDGE program.

C) thalidomide.

Thalidomide is indeed associated with severe teratogenic effects and has a restricted distribution program, but it is not the medication specifically managed by the iPLEDGE program. The iPLEDGE program is uniquely focused on isotretinoin, despite thalidomide's historical significance regarding teratogenicity.

D) isotretinoin.

Isotretinoin is the correct answer, as it is a powerful retinoid used primarily for severe acne and is known for its significant teratogenic risks. The iPLEDGE program was established to prevent these risks by enforcing strict protocols for prescribing and dispensing the medication to ensure that patients are not pregnant or do not become pregnant while on the treatment.

Conclusion

Isotretinoin is the medication governed by the iPLEDGE program due to its severe teratogenic risks, making option D the definitive correct choice. Other options, while they may have associated risks, do not involve the same level of teratogenic concern or regulatory oversight as isotretinoin. Thus, they cannot fulfill the criteria set by the iPLEDGE program.